Cover Image

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study

Objective: Adalimumab (ADA) is an effective treatment for inflammatory bowel disease (IBD), both ulcerative colitis (UC) and Crohn's disease (CD). The equal effect between the original ADA and biosimilars from Europe and the United States has been shown. However, the biosimilar of ADA is differ...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Wang (Author), Xiaofei Li (Author), Yanting Shi (Author), He Zhou (Author), Gang Yang (Author), Ruixia Li (Author), Tong Wu (Author), Jie Liang (Author)
Format: Book
Published: Frontiers Media S.A., 2023-10-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items